Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DCB-202
- Development stage
- Preclinical
- Lead developer
- Dewcell Biotherapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
DCB-202 is an investigational cell-derived therapy being developed by Dewcell Biotherapeutics. It consists of artificial platelet-like particles (i-aPLP™) generated from induced pluripotent stem cells (iPSCs) using the company's proprietary en-aPLT™ (engineered artificial platelet) production platform. Unlike conventional donor-derived platelet transfusions, DCB-202 is designed as an off-the-shelf, pathogen-free product that mimics the physiological functions of natural platelets. It is primarily intended for applications in hemostasis and regenerative medicine, potentially serving as a stable alternative for treating bleeding disorders or as a specialized vehicle for targeted drug delivery.
- Other names
- i-aPLPiPSC-derived artificial platelet-like particle
Beyond the preview
Go deeper on DCB-202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DCB-202.